# ImmuneMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunemed

- Industry: Biotechnology
- Headquarters: Chuncheon, South Korea
- Website: www.immunemed.co.kr
- Total disclosed funding: $25M
- Latest round: Series C (Mar 26, 2019)
- Investors on record: 8

## About

Founded in 2000 and based in Chuncheon, South Korea, ImmuneMed Inc. operates as a biopharmaceutical company that researches and develops antiviral agents. The company also produces diagnostic kits for infectious diseases. In June 2023, ImmuneMed Inc. raised KRW 2.5 billion in venture funding from investors Meta Investment, SV Investment, and UTC Investment, valuing the company at KRW 429.6 billion post-money.

## Funding rounds

- Series C, Mar 26, 2019, $14M — UTC Investment, Laguna Investment, Tigris Investment, UNO Investment
- Series B, Oct 13, 2017, $6.2M — JB Investment, SV Investment, UTC Investment
- Series A, Sep 26, 2015, $4.2M — KDB Capital, SV Investment, Sejong Venture Partners

## Investors

- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series A
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A, Series B
- Sejong Venture Partners — Series A
- JB Investment (https://capitalatlas.ai/funds/jb-investment) — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B, Series C
- Laguna Investment (https://capitalatlas.ai/funds/laguna-investment) — Series C
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series C
- UNO Investment — Series C